Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency

Thrombosis Research

Volumn 123, Issue SUPPL. 1, 2008, Pages

  Clark, N P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; GERIATRIC PATIENT; HUMAN; KIDNEY FAILURE; OBESITY; PRIORITY JOURNAL; SUBDURAL HEMATOMA; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OBESITY; RENAL INSUFFICIENCY; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 55249087388     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.08.005     Document Type: Article

References (14)

1. Hirsch J., and Raschke R. Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
2. Cook L.M., Kahn S.R., Goodwin J., and Kovacs M.J. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 5 (2007) 937-941
3. Scholten D.J., Hoedema R.M., and Scholten S.E. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12 (2002) 19-24
4. Fragmin product information. http://www.fragmin.com/professionals/prescribing.php. Accessed September 2007.
5. Al-Yaseen E., Wells P.S., Anderson J., Martin J., and Kovacs J. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 3 (2005) 100-102
6. Spinler S.A., Inverso S.M., Cohen M., Goodman S.G., Stringer K.A., and Antman E.M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146 (2003) 33-41
7. Lovenox product information. http://products.sanofi-aventis.us/lovenox/lovenox.html. Accessed September 2007.
8. Pautas E., Gouin I., Bellot O., Andreux J., and Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Safety 25 (2002) 725-733
9. Mahe I., Gouin-Thibault I., Drouet L., Simoneau G., Di Castilla H., Siguret V., et al. Elderly medical patients treated with prophylactic dosages of enoxaparin. Drugs Aging 24 (2007) 63-71
10. Lim W., Dentali F., Eikelboom J.W., and Crowther M.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006) 673-684
11. Fox K., Antman E.M., Montalescot G., Agewall S., SomaRaju B., Verheugt F.W.A., et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49 (2007) 2249-2255
12. Montalescot G., Collet J.P., Tunguy M.L., Ankri A., Pyot L., Dumaine R., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110 (2004) 392-398
13. Kruse M.W., and Lee J.J. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal failure. Am Heart J 148 (2004) 582-589
14. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401S-428S